PDS Biotech 
Welcome,         Profile    Billing    Logout  
  Products    Diseases   Products    Trials    News 
13 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
PDS01ADC / PDS Biotech
NCT04491955: Phase II Trial of Combination Immunotherapy in Subjects With Advanced Small Bowel and Colorectal Cancers

Completed
2
32
US
CV301, MSB0011359C, N-803, NHS-IL12
National Cancer Institute (NCI)
Small Bowel Cancers, Colorectal Cancers
10/22
08/24
NCT05361798: T-Cell Clonality After Stereotactic Body Radiation Therapy Alone and in Combination With the Immunocytokine M9241 in Localized High- and Intermediate-Risk Prostate Cancer Treated With Androgen Deprivation Therapy

Recruiting
2
65
US
M9241, Stereotactic Body Radiation Therapy (SBRT)
National Cancer Institute (NCI)
Cancer Of Prostate
08/26
12/26
NCT05286814: PDS01ADC in Combination With Hepatic Artery Infusion Pump (HAIP) and Systemic Therapy for Subjects With Metastatic Colorectal Cancer, Intrahepatic Cholangiocarcinoma, or Metastatic Adrenocortical Carcinoma

Recruiting
2
70
US
Floxuridine, 5-Fluorouracil, Irinotecan, Intera 3000 Hepatic Artery Infusion Pump (HAIP), Oxaliplatin, Leucovorin, PDS01ADC, Gemcitabine, Dexamethasone
National Cancer Institute (NCI)
Metastatic Colorectal Cancer (Mcrc), Intrahepatic Cholangiocarcinoma (Icc), Colorectal Cancer, Colorectal Neoplasms, Cholangiocarcinoma, Intrahepatic Bile Duct Cancer, Bile Duct Cancer, Bile Duct Neoplasms
12/27
12/28
NCT06096870: Enzalutamide and PDS01ADC in PET Positive Recurrent Prostate Cancer (pprPC) Without Testosterone Lowering Therapy

Recruiting
2
65
US
Enzalutamide, PDS01ADC
National Cancer Institute (NCI)
Prostate Cancer, Recurrent Prostate Cancer, PET Positive
12/28
12/29
NCT04287868: Combination Immunotherapy in Subjects With Advanced HPV Associated Malignancies

Active, not recruiting
1/2
51
US
PDS0101, M7824, MSB0011395C, NHS-IL12
National Cancer Institute (NCI)
Cervical Cancer, HPV Cancers, Anal Cancer, Oropharyngeal Cancer, Vulvar, Vaginal, Penile, Rectal Cancer
07/22
07/26
21-C-0001, NCT04633252: M9241 in Combination With Docetaxel in Adults With Metastatic Castration Sensitive and Castration Resistant Prostate Cancer

Recruiting
1/2
86
US
ADT, Prednisone, M7824, Docetaxel, M9241
National Cancer Institute (NCI)
Cancer Of Prostate, Prostate Neoplasms
12/26
12/26
NCT04708470: A Phase I/II Study of Combination Immunotherapy for Advanced Cancers Including HPV-Associated Malignancies, Small Bowel, and Colon Cancers

Active, not recruiting
1/2
55
US
Bintrafusp Alfa, PDS01ADC, Entinostat
National Cancer Institute (NCI)
Oropharyngeal Cancer, Neck Cancer, Human Papillomavirus, HPV, Anal Cancer, Cervical Cancer, Penile Cancer, Vulvar Cancer, Vaginal Cancer, Colon Cancer
12/25
12/26
NCT04303117: NHS-IL12 Monotherapy and in Combination With M7824 in Advanced Kaposi Sarcoma

Recruiting
1/2
80
US
NHS-IL12, M7824
National Cancer Institute (NCI)
Kaposi Sarcoma
09/25
12/28
20-C-0012, NCT04235777: Bintrafusp Alfa (M7824) and PDS01ADC Alone and in Combination With Stereotactic Body Radiation Therapy (SBRT) in Adults With Metastatic Non-Prostate Genitourinary Malignancies

Recruiting
1
100
US
Stereotactic body radiation therapy (SBRT), PDS01ADC, M7824
National Cancer Institute (NCI)
Urothelial Cancer, Bladder Cancer, Genitourinary Cancer, Urogenital Neoplasms, Urogenital Cancer
12/27
12/27
Versamune HPV / PDS Biotech
NCT06790966: Phase 3 Study of PDS0101 and Pembrolizumab in HPV16+ Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

Recruiting
3
351
US
Combination Treatment of PDS0101 and Pembrolizumab, Versamune HPV, KEYTRUDA, Pembrolizumab Monotherapy
PDS Biotechnology Corp.
Recurrent Head and Neck Cancer, Metastatic Head and Neck Cancer, HPV Positive Oropharyngeal Squamous Cell Carcinoma, Neoplasms, Head and Neck, Unresectable Head and Neck Squamous Cell Carcinoma
02/29
02/29
IMMUNOCERV, NCT04580771: A Vaccine (PDS0101) and Chemoradiation for the Treatment of Stage IB3-IVA Cervical Cancer, the Trial

Active, not recruiting
2
22
US
Cisplatin, Abiplatin, Blastolem, Briplatin, CDDP, Cis-diammine-dichloroplatinum, Cis-diamminedichloridoplatinum, Cis-diamminedichloro Platinum (II), Cis-diamminedichloroplatinum, Cis-dichloroammine Platinum (II), Cis-platinous Diamine Dichloride, Cis-platinum, Cis-platinum II, Cis-platinum II Diamine Dichloride, Cismaplat, Cisplatina, Cisplatinum, Cisplatyl, Citoplatino, Citosin, Cysplatyna, DDP, Lederplatin, Metaplatin, Neoplatin, Peyrone''s Chloride, Peyrone''s Salt, Placis, Plastistil, Platamine, Platiblastin, Platiblastin-S, Platinex, Platinol, Platinol- AQ, Platinol-AQ, Platinol-AQ VHA Plus, Platinoxan, Platinum, Platinum Diamminodichloride, Platiran, Platistin, Platosin, Liposomal HPV-16 E6/E7 Multipeptide Vaccine PDS0101, mmunoMAPK-RDOTAP /HPV-16 E6/E7 Peptide Antigen Vaccine, PDS0101, Radiation Therapy, Cancer Radiotherapy, Irradiate, Irradiated, Irradiation, Radiation, Radiation Therapy, NOS, Radiotherapeutics, Radiotherapy, RT, Therapy, Radiation
M.D. Anderson Cancer Center, National Cancer Institute (NCI)
Locally Advanced Cervical Squamous Cell Carcinoma, Not Otherwise Specified, Stage IB3 Cervical Cancer FIGO 2018, Stage II Cervical Cancer FIGO 2018, Stage IIA Cervical Cancer FIGO 2018, Stage IIA1 Cervical Cancer FIGO 2018, Stage IIA2 Cervical Cancer FIGO 2018, Stage IIB Cervical Cancer FIGO 2018, Stage III Cervical Cancer FIGO 2018, Stage IIIA Cervical Cancer FIGO 2018, Stage IIIB Cervical Cancer FIGO 2018, Stage IIIC Cervical Cancer FIGO 2018, Stage IIIC1 Cervical Cancer FIGO 2018, Stage IIIC2 Cervical Cancer FIGO 2018, Stage IVA Cervical Cancer FIGO 2018
03/27
03/27
VERSATILE-002, NCT04260126: Study of PDS0101 and Pembrolizumab Combination I/O in Subjects with HPV16 + Recurrent And/or Metastatic HNSCC

Checkmark Data from VERSATILE-002 clinical trial in combination with PDS0101 for metastatic head and neck cancer at MHNCS 2022
Feb 2022 - Feb 2022: Data from VERSATILE-002 clinical trial in combination with PDS0101 for metastatic head and neck cancer at MHNCS 2022
Active, not recruiting
2
95
Europe, US
Pembrolizumab (KEYTRUDA®) and PDS0101
PDS Biotechnology Corp., Merck Sharp & Dohme LLC
Metastatic Head and Neck Cancer, Recurrent Head and Neck Cancer, HPV Positive Oropharyngeal Squamous Cell Carcinoma, Neoplasms, Head and Neck
06/25
06/25
NCT05232851: A Vaccine (PDS0101) Alone or in Combination With Pembrolizumab for the Treatment of Locally Advanced Human Papillomavirus-Associated Oropharynx Cancer

Active, not recruiting
1/2
24
US
Liposomal HPV-16 E6/E7 Multipeptide Vaccine PDS0101, mmunoMAPK-RDOTAP /HPV-16 E6/E7 Peptide Antigen Vaccine, PDS0101, Pembrolizumab, BCD-201, Biosimilar BCD-201, Keytruda, Lambrolizumab, MK-3475, SCH 900475, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, computerized axial tomography, Computerized Tomography, CT, CT SCAN, tomography, FDG-Positron Emission Tomography, FDG, FDG-PET, FDG-PET Imaging, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Biopsy, BIOPSY_TYPE, Bx
Mayo Clinic
Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Human Papillomavirus-Related Carcinoma, Locally Advanced Oropharyngeal Carcinoma, Stage IVA Oropharyngeal (p16-Negative) Carcinoma AJCC v8, Stage IVB Oropharyngeal (p16-Negative) Carcinoma AJCC v8
10/26
10/26
PDS0102 / National Cancer Institute, PDS Biotech
No trials found
PDS0203 / PDS Biotech, Farmacore, Blanver
No trials found
PDS0204 / PDS Biotech, Farmacore
No trials found
Versamune MUC1 / PDS Biotech
No trials found
PDS0104 / PDS Biotech
No trials found
Undisclosed TARP peptide vaccine / National Cancer Institute, PDS Biotech
No trials found
TARP dendritic cell vaccine / PDS Biotech
No trials found
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
PDS01ADC / PDS Biotech
NCT04491955: Phase II Trial of Combination Immunotherapy in Subjects With Advanced Small Bowel and Colorectal Cancers

Completed
2
32
US
CV301, MSB0011359C, N-803, NHS-IL12
National Cancer Institute (NCI)
Small Bowel Cancers, Colorectal Cancers
10/22
08/24
NCT05361798: T-Cell Clonality After Stereotactic Body Radiation Therapy Alone and in Combination With the Immunocytokine M9241 in Localized High- and Intermediate-Risk Prostate Cancer Treated With Androgen Deprivation Therapy

Recruiting
2
65
US
M9241, Stereotactic Body Radiation Therapy (SBRT)
National Cancer Institute (NCI)
Cancer Of Prostate
08/26
12/26
NCT05286814: PDS01ADC in Combination With Hepatic Artery Infusion Pump (HAIP) and Systemic Therapy for Subjects With Metastatic Colorectal Cancer, Intrahepatic Cholangiocarcinoma, or Metastatic Adrenocortical Carcinoma

Recruiting
2
70
US
Floxuridine, 5-Fluorouracil, Irinotecan, Intera 3000 Hepatic Artery Infusion Pump (HAIP), Oxaliplatin, Leucovorin, PDS01ADC, Gemcitabine, Dexamethasone
National Cancer Institute (NCI)
Metastatic Colorectal Cancer (Mcrc), Intrahepatic Cholangiocarcinoma (Icc), Colorectal Cancer, Colorectal Neoplasms, Cholangiocarcinoma, Intrahepatic Bile Duct Cancer, Bile Duct Cancer, Bile Duct Neoplasms
12/27
12/28
NCT06096870: Enzalutamide and PDS01ADC in PET Positive Recurrent Prostate Cancer (pprPC) Without Testosterone Lowering Therapy

Recruiting
2
65
US
Enzalutamide, PDS01ADC
National Cancer Institute (NCI)
Prostate Cancer, Recurrent Prostate Cancer, PET Positive
12/28
12/29
NCT04287868: Combination Immunotherapy in Subjects With Advanced HPV Associated Malignancies

Active, not recruiting
1/2
51
US
PDS0101, M7824, MSB0011395C, NHS-IL12
National Cancer Institute (NCI)
Cervical Cancer, HPV Cancers, Anal Cancer, Oropharyngeal Cancer, Vulvar, Vaginal, Penile, Rectal Cancer
07/22
07/26
21-C-0001, NCT04633252: M9241 in Combination With Docetaxel in Adults With Metastatic Castration Sensitive and Castration Resistant Prostate Cancer

Recruiting
1/2
86
US
ADT, Prednisone, M7824, Docetaxel, M9241
National Cancer Institute (NCI)
Cancer Of Prostate, Prostate Neoplasms
12/26
12/26
NCT04708470: A Phase I/II Study of Combination Immunotherapy for Advanced Cancers Including HPV-Associated Malignancies, Small Bowel, and Colon Cancers

Active, not recruiting
1/2
55
US
Bintrafusp Alfa, PDS01ADC, Entinostat
National Cancer Institute (NCI)
Oropharyngeal Cancer, Neck Cancer, Human Papillomavirus, HPV, Anal Cancer, Cervical Cancer, Penile Cancer, Vulvar Cancer, Vaginal Cancer, Colon Cancer
12/25
12/26
NCT04303117: NHS-IL12 Monotherapy and in Combination With M7824 in Advanced Kaposi Sarcoma

Recruiting
1/2
80
US
NHS-IL12, M7824
National Cancer Institute (NCI)
Kaposi Sarcoma
09/25
12/28
20-C-0012, NCT04235777: Bintrafusp Alfa (M7824) and PDS01ADC Alone and in Combination With Stereotactic Body Radiation Therapy (SBRT) in Adults With Metastatic Non-Prostate Genitourinary Malignancies

Recruiting
1
100
US
Stereotactic body radiation therapy (SBRT), PDS01ADC, M7824
National Cancer Institute (NCI)
Urothelial Cancer, Bladder Cancer, Genitourinary Cancer, Urogenital Neoplasms, Urogenital Cancer
12/27
12/27
Versamune HPV / PDS Biotech
NCT06790966: Phase 3 Study of PDS0101 and Pembrolizumab in HPV16+ Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

Recruiting
3
351
US
Combination Treatment of PDS0101 and Pembrolizumab, Versamune HPV, KEYTRUDA, Pembrolizumab Monotherapy
PDS Biotechnology Corp.
Recurrent Head and Neck Cancer, Metastatic Head and Neck Cancer, HPV Positive Oropharyngeal Squamous Cell Carcinoma, Neoplasms, Head and Neck, Unresectable Head and Neck Squamous Cell Carcinoma
02/29
02/29
IMMUNOCERV, NCT04580771: A Vaccine (PDS0101) and Chemoradiation for the Treatment of Stage IB3-IVA Cervical Cancer, the Trial

Active, not recruiting
2
22
US
Cisplatin, Abiplatin, Blastolem, Briplatin, CDDP, Cis-diammine-dichloroplatinum, Cis-diamminedichloridoplatinum, Cis-diamminedichloro Platinum (II), Cis-diamminedichloroplatinum, Cis-dichloroammine Platinum (II), Cis-platinous Diamine Dichloride, Cis-platinum, Cis-platinum II, Cis-platinum II Diamine Dichloride, Cismaplat, Cisplatina, Cisplatinum, Cisplatyl, Citoplatino, Citosin, Cysplatyna, DDP, Lederplatin, Metaplatin, Neoplatin, Peyrone''s Chloride, Peyrone''s Salt, Placis, Plastistil, Platamine, Platiblastin, Platiblastin-S, Platinex, Platinol, Platinol- AQ, Platinol-AQ, Platinol-AQ VHA Plus, Platinoxan, Platinum, Platinum Diamminodichloride, Platiran, Platistin, Platosin, Liposomal HPV-16 E6/E7 Multipeptide Vaccine PDS0101, mmunoMAPK-RDOTAP /HPV-16 E6/E7 Peptide Antigen Vaccine, PDS0101, Radiation Therapy, Cancer Radiotherapy, Irradiate, Irradiated, Irradiation, Radiation, Radiation Therapy, NOS, Radiotherapeutics, Radiotherapy, RT, Therapy, Radiation
M.D. Anderson Cancer Center, National Cancer Institute (NCI)
Locally Advanced Cervical Squamous Cell Carcinoma, Not Otherwise Specified, Stage IB3 Cervical Cancer FIGO 2018, Stage II Cervical Cancer FIGO 2018, Stage IIA Cervical Cancer FIGO 2018, Stage IIA1 Cervical Cancer FIGO 2018, Stage IIA2 Cervical Cancer FIGO 2018, Stage IIB Cervical Cancer FIGO 2018, Stage III Cervical Cancer FIGO 2018, Stage IIIA Cervical Cancer FIGO 2018, Stage IIIB Cervical Cancer FIGO 2018, Stage IIIC Cervical Cancer FIGO 2018, Stage IIIC1 Cervical Cancer FIGO 2018, Stage IIIC2 Cervical Cancer FIGO 2018, Stage IVA Cervical Cancer FIGO 2018
03/27
03/27
VERSATILE-002, NCT04260126: Study of PDS0101 and Pembrolizumab Combination I/O in Subjects with HPV16 + Recurrent And/or Metastatic HNSCC

Checkmark Data from VERSATILE-002 clinical trial in combination with PDS0101 for metastatic head and neck cancer at MHNCS 2022
Feb 2022 - Feb 2022: Data from VERSATILE-002 clinical trial in combination with PDS0101 for metastatic head and neck cancer at MHNCS 2022
Active, not recruiting
2
95
Europe, US
Pembrolizumab (KEYTRUDA®) and PDS0101
PDS Biotechnology Corp., Merck Sharp & Dohme LLC
Metastatic Head and Neck Cancer, Recurrent Head and Neck Cancer, HPV Positive Oropharyngeal Squamous Cell Carcinoma, Neoplasms, Head and Neck
06/25
06/25
NCT05232851: A Vaccine (PDS0101) Alone or in Combination With Pembrolizumab for the Treatment of Locally Advanced Human Papillomavirus-Associated Oropharynx Cancer

Active, not recruiting
1/2
24
US
Liposomal HPV-16 E6/E7 Multipeptide Vaccine PDS0101, mmunoMAPK-RDOTAP /HPV-16 E6/E7 Peptide Antigen Vaccine, PDS0101, Pembrolizumab, BCD-201, Biosimilar BCD-201, Keytruda, Lambrolizumab, MK-3475, SCH 900475, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, computerized axial tomography, Computerized Tomography, CT, CT SCAN, tomography, FDG-Positron Emission Tomography, FDG, FDG-PET, FDG-PET Imaging, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Biopsy, BIOPSY_TYPE, Bx
Mayo Clinic
Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Human Papillomavirus-Related Carcinoma, Locally Advanced Oropharyngeal Carcinoma, Stage IVA Oropharyngeal (p16-Negative) Carcinoma AJCC v8, Stage IVB Oropharyngeal (p16-Negative) Carcinoma AJCC v8
10/26
10/26
PDS0102 / National Cancer Institute, PDS Biotech
No trials found
PDS0203 / PDS Biotech, Farmacore, Blanver
No trials found
PDS0204 / PDS Biotech, Farmacore
No trials found
Versamune MUC1 / PDS Biotech
No trials found
PDS0104 / PDS Biotech
No trials found
Undisclosed TARP peptide vaccine / National Cancer Institute, PDS Biotech
No trials found
TARP dendritic cell vaccine / PDS Biotech
No trials found

Download Options